WO2021196443A1 - Préparation liquide d'un anticorps monoclonal anti-pd-1 humanisé recombinant - Google Patents

Préparation liquide d'un anticorps monoclonal anti-pd-1 humanisé recombinant Download PDF

Info

Publication number
WO2021196443A1
WO2021196443A1 PCT/CN2020/101516 CN2020101516W WO2021196443A1 WO 2021196443 A1 WO2021196443 A1 WO 2021196443A1 CN 2020101516 W CN2020101516 W CN 2020101516W WO 2021196443 A1 WO2021196443 A1 WO 2021196443A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
buffer
liquid preparation
polysorbate
sucrose
Prior art date
Application number
PCT/CN2020/101516
Other languages
English (en)
Chinese (zh)
Inventor
赵丽丽
石曼
刘忠
Original Assignee
鲁南制药集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 鲁南制药集团股份有限公司 filed Critical 鲁南制药集团股份有限公司
Publication of WO2021196443A1 publication Critical patent/WO2021196443A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

  • the invention belongs to the field of pharmaceutical preparations, and specifically relates to a liquid preparation of a recombinant humanized anti-PD-1 monoclonal antibody.
  • PD-1 is an immunosuppressive receptor, mainly in activated T cells and B cells, as a T cell inhibitory receptor, combined with the ligand PD-L1 can inhibit the activity of T lymphocytes and related in vivo cellular immunity Responses can limit the function of T cell effectors in tumor cells and play an important role in tumor immune escape.
  • the anti-PD-1 monoclonal antibody can block the programmed death (PD)-1 receptor on the surface of activated T cells, and can save exhausted T cells by inhibiting the PD-1 and PD-1 ligand (PD-L1) pathways , Enhance anti-tumor immunity, and have good targeting potential in the treatment of tumors.
  • Patent CN103429264A discloses a lyophilized preparation of anti-human PD-1 antibody or its antigen-binding fragment, comprising: 25mg/ml anti-human PD-1 antibody or its antigen-binding fragment, 10mM pH 5.0-6.0 Histidine buffer, 70mg/ml sucrose, 0.02mg/ml polysorbate 80.
  • Patent CN107334728A discloses a solution preparation of anti-human PD-1 monoclonal antibody, comprising 100mg/ml of anti-human PD-1 monoclonal antibody, 20mM histidine buffer, 250mM sucrose, 6 ⁇ 8mg/ml Poloxamer 188, 20-100mg/ml sulfobutyl ether ⁇ -cyclodextrin, and 2-8mg/ml benzyl alcohol.
  • Patent CN107325180A discloses an anti-human PD-1 monoclonal antibody preparation suitable for subcutaneous injection, comprising 100 mg/ml of anti-human PD-1 monoclonal antibody, 10 mM phosphate buffer, and 10 mM citrate buffer , 250mM mannitol, 20mM amino acid, 8mg/ml Tween 20.
  • Patent CN106390115A discloses a stable formulation of humanized monoclonal antibody, including 25-50mg/ml, 10-20mM citrate buffer with pH 6.0, 150mM mannitol and 50mM sodium chloride, 0.20% polysorbate Ester 80.
  • CN107198773A discloses a liquid preparation of recombinant anti-PD-L1 fully human monoclonal antibody, comprising 30mg/ml recombinant anti-PD-L1 fully human monoclonal antibody, 20mM histidine-histidine hydrochloride, 150mM mannitol, 55mM chlorine Sodium sulfide and 0.01wt% polysorbate 80.
  • CN105793288A discloses an aqueous pharmaceutical formulation of PDL1 monoclonal antibody, comprising 60 mg/ml of anti-PDL1 monoclonal antibody, 20 mM histidine acetate or sodium acetate buffer, 120 mM sucrose, and pH 5.8.
  • CN110354073A discloses a liquid preparation of immunosuppressant monoclonal antibody, comprising 25mg/ml aglycosylated anti-PD-1 monoclonal antibody, 15mM histidine pH6.0, 270mM sucrose and 0.4mg/ml Polysorbate 20. It is relatively stable when placed at 2 ⁇ 8°C for 6 months, but its stability in a higher temperature environment needs to be further improved. Therefore, it is also necessary to provide a more stable liquid formulation of aglycosylated anti-PD-1 monoclonal antibody.
  • the purpose of the present invention is to provide a stable liquid preparation of recombinant humanized anti-PD-1 monoclonal antibody.
  • a liquid preparation of recombinant humanized anti-PD-1 monoclonal antibody containing 10mg/ml aglycosylated anti-PD-1 monoclonal antibody, 10 ⁇ 20mM buffer, 220 ⁇ 270mM stabilizer, 0.02 ⁇ 0.06% increase Solvent and buffer system adjust the pH to 5.5 ⁇ 6.5.
  • the buffer is histidine hydrochloric acid or citric acid/sodium citrate, more preferably histidine hydrochloric acid.
  • the stabilizer is sucrose or mannitol; more preferably, sucrose.
  • the solubilizer is polysorbate 80 or polysorbate 20.
  • a liquid preparation of recombinant humanized anti-PD-1 monoclonal antibody comprising 10 mg/ml aglycosylated anti-PD-1 monoclonal antibody, 10-20 mM histidine hydrochloric acid buffer solution , 220 ⁇ 250mM sucrose, 0.02 ⁇ 0.06%(w/v) polysorbate 80, the buffer system adjusts the pH to 6.0 ⁇ 6.5.
  • the concentration of the histidine hydrochloric acid buffer solution is 10 mM.
  • the sucrose concentration is 220 mM.
  • the content of the polysorbate 80 is 0.02% (w/v).
  • the pH is 6.0.
  • a liquid preparation of recombinant humanized anti-PD-1 monoclonal antibody contains the following components:
  • the present invention also provides a method for preparing the liquid preparation of the recombinant humanized anti-PD-1 monoclonal antibody.
  • the method includes the following steps: weighing a prescribed amount of buffer, adding water for injection to dissolve, adjusting the pH, and The buffer system prepared above is concentrated by ultrafiltration and the original buffer system of the non-glycosylated anti-PD-1 monoclonal antibody protein is replaced by the original buffer system of the non-glycosylated anti-PD-1 monoclonal antibody protein, and then the prescription amount of sucrose and polysorbate is added. 80. Stir evenly, then use the buffer system to adjust the protein concentration to 10mg/ml, sterile filter through 0.22 ⁇ m membrane, and then fill it.
  • the aglycosylated anti-PD-1 monoclonal antibody of the present invention can be prepared with reference to CN106519034A, and the heavy chain and light chain sequences of the aglycosylated anti-PD-1 monoclonal antibody are as follows:
  • the present invention provides a liquid preparation suitable for intravenous administration, which can maintain stability during storage and has lower aggregates and fragmentation.
  • a liquid preparation suitable for intravenous administration which can maintain stability during storage and has lower aggregates and fragmentation.
  • the appearance, concentration, pH, antibody purity and charge heterogeneity of the preparation did not change significantly.
  • the appearance, concentration, activity, pH value, purity (SEC-HPLC) and charge heterogeneity (CEX-HPLC) of the preparation did not change significantly.
  • the following examples are used to further illustrate the present invention.
  • the listed cases are only part of the preparation screening test, and therefore, the present invention cannot be limited to the scope of the described examples.
  • the test methods for specific conditions not specified in the following examples are selected according to conventional methods and conditions, or according to the product specification.
  • the stability test and related biological tests were carried out in accordance with the specifications of the Chinese Pharmacopoeia.
  • the facts described in the examples are all medicinal grades, and they are all sold in the market.
  • the aglycosylated anti-PD-1 monoclonal antibody can be prepared by referring to the method of CN106519034A.
  • the preparation method is as in Example 1.
  • the preparation method is as in Example 1.
  • the preparation method is as in Example 1.
  • the preparation method is as in Example 1.
  • the preparation method is the same as in Example 1.
  • the preparation method is the same as in Example 1.
  • the long-term test is carried out under the condition of 2 ⁇ 8°C, and the tests are carried out at the end of 0 month, 3 months, 6 months, 12 months, and 24 months respectively according to the stability key inspection items; accelerated test at 25°C ⁇ 2°C Under the conditions, the time is 6 months, the equipment used can control the temperature ⁇ 2°C, and detect the actual temperature. During the test period, samples will be taken at the end of the 0th, 3rd, and 6th months, and tested according to the stability key inspection items. . The results are shown in Table 1 and Table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation liquide d'un anticorps monoclonal anti-PD-1 humanisé recombinant. La préparation liquide contient 10 mg/ml d'un anticorps monoclonal anti-PD-1 aglycosylé, de 10 à 20 mM d'un tampon, de 220 à 270 mM d'un stabilisateur, et de 0,02 à 0,06 % (p/v) d'un agent solubilisant, et un système tampon régule le pH à 5,5-6,5. En optimisant davantage le contenu de la solution tampon, du stabilisateur et de l'agent solubilisant, on obtient une préparation liquide adaptée à l'administration intraveineuse, qui peut conserver sa stabilité pendant le stockage et qui présente une spécificité et une fragmentation plus faibles. Après que la préparation ait été placée à une température de 2 à 8 °C pendant 24 mois, l'apparence, la concentration et le pH de la préparation ainsi que la pureté et l'hétérogénéité de charge d'un anticorps ne sont pas manifestement modifiés.
PCT/CN2020/101516 2020-03-30 2020-07-11 Préparation liquide d'un anticorps monoclonal anti-pd-1 humanisé recombinant WO2021196443A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010235536.7 2020-03-30
CN202010235536.7A CN113456582B (zh) 2020-03-30 2020-03-30 重组人源化抗pd-1单克隆抗体的液体制剂

Publications (1)

Publication Number Publication Date
WO2021196443A1 true WO2021196443A1 (fr) 2021-10-07

Family

ID=77864792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/101516 WO2021196443A1 (fr) 2020-03-30 2020-07-11 Préparation liquide d'un anticorps monoclonal anti-pd-1 humanisé recombinant

Country Status (2)

Country Link
CN (1) CN113456582B (fr)
WO (1) WO2021196443A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117427157A (zh) * 2023-10-30 2024-01-23 广州誉衡生物科技有限公司 一种全人源抗pd-1单克隆抗体的稳定制剂

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114099672B (zh) * 2022-01-28 2022-05-06 嘉和生物药业有限公司 具有增强稳定性的抗rankl人源化单克隆抗体的药物组合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
WO2016109822A1 (fr) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation d'anticorps thérapeutiques aglycosylés
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
CN107325180A (zh) * 2016-04-28 2017-11-07 上海抗体药物国家工程研究中心有限公司 一种适于皮下注射的抗人pd-1的单克隆抗体制剂
WO2018060210A1 (fr) * 2016-09-27 2018-04-05 Ares Trading S.A. Composition pharmaceutique liquide
CN110354073A (zh) * 2018-04-09 2019-10-22 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
CN103429264A (zh) * 2011-03-31 2013-12-04 默沙东公司 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗
WO2016109822A1 (fr) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation d'anticorps thérapeutiques aglycosylés
CN107325180A (zh) * 2016-04-28 2017-11-07 上海抗体药物国家工程研究中心有限公司 一种适于皮下注射的抗人pd-1的单克隆抗体制剂
WO2018060210A1 (fr) * 2016-09-27 2018-04-05 Ares Trading S.A. Composition pharmaceutique liquide
CN107198773A (zh) * 2017-06-08 2017-09-26 上海药明生物技术有限公司 重组抗pd‑l1全人单克隆抗体的液体制剂
CN110354073A (zh) * 2018-04-09 2019-10-22 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117427157A (zh) * 2023-10-30 2024-01-23 广州誉衡生物科技有限公司 一种全人源抗pd-1单克隆抗体的稳定制剂

Also Published As

Publication number Publication date
CN113456582B (zh) 2024-06-14
CN113456582A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
CN108367072B (zh) 含抗-pd-l1抗体avelumab的水性药物制剂
EP3085385B1 (fr) Composition pharmaceutique contenant de l'adalimumab
US11291725B2 (en) Liquid pharmaceutical composition
US20100189721A1 (en) Antibody formulations
TW201513882A (zh) 抗－催乳激素受體抗體調配物
CN110354073B (zh) 一种免疫抑制剂单克隆抗体的液体制剂
JP7379159B2 (ja) 水性抗ｐｄ－ｌ１抗体製剤
WO2021196443A1 (fr) Préparation liquide d'un anticorps monoclonal anti-pd-1 humanisé recombinant
JP7407723B2 (ja) ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物
US20210188996A1 (en) Formulations of anti-cd38 antibodies for subcutaneous administration
TW202023603A (zh) 包含vegf拮抗物之液體組成物
WO2021249373A1 (fr) Préparation liquide stable à haute concentration d'anticorps monoclonal anti-humain il-5
WO2021259101A1 (fr) Préparation lyophilisée d'anticorps monoclonaux anti-her2 et procédé de préparation
WO2021147854A1 (fr) Préparations d'anticorps monoclonaux anti-tigit recombinants entièrement humains, leur procédé de préparation et leur utilisation
CN111683681B (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
CN114007648B (zh) 包含抗lag-3抗体的制剂、其制备方法及其用途
CN110392578B (zh) 水性抗pd-l1抗体制剂
KR20240038005A (ko) B7-h3 항체의 약학적 조성물 및 그것의 용도
CN118076380A (zh) 免疫检查点抑制剂的药物配制物
CN113081955A (zh) 一种免疫抑制剂单克隆抗体的制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20929063

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20929063

Country of ref document: EP

Kind code of ref document: A1